Literature DB >> 12109515

Fuzzy logic-based tumor-marker profiles improved sensitivity in the diagnosis of lung cancer.

Joachim Schneider1, Norman Bitterlich, Hans-Georg Velcovsky, Harald Morr, Norbert Katz, Erich Eigenbrodt.   

Abstract

BACKGROUND: The aim of this study was to improve the diagnostic efficiency of tumor markers in the diagnosis of lung cancer, by the mathematical evaluation of a tumor marker profile employing fuzzy logic modelling.
METHODS: A panel of four tumor markers, i.e., carcinoembryonic antigen (CEA), cytokeratin 19 antibody (CYFRA 21-1), neuron-specific enolase (NSE), squamous cell carcinoma-related antigen (SCC) and, additionally, C-reactive protein (CRP), was measured in 175 newly diagnosed lung cancer patients with different histological types and stages. Results were compared with those in 120 control subjects, including 27 with chronic obstructive pulmonary diseases (COPD), 65 with pneumoconiosis, and 11 persons with acute inflammatory lung diseases. A classificator was developed using a fuzzy-logic rule-based system.
RESULTS: Application of the fuzzy-logic rule-based system to the tumor marker values of CYFRA 21-1, NSE, and CRP yielded an increase in sensitivity of approximately 20%, i.e., 92%, compared with that of the best single marker, CYFRA 21-1(sensitivity, 72%). The corresponding specificity was 95%. The fuzzy classificator significantly improved the sensitivity of the tumor marker panel in stages I and IIIa for non-small-cell lung cancer, as well as in "limited disease" status for small-cell lung cancer. Also, the diagnosis of other stages of lung cancer was enhanced.
CONCLUSION: Fuzzy-logic analysis was proven to be more powerful than the measurement of single markers alone or combinations using multiple logistic regression analysis of all markers. Therefore, fuzzy logic offers a promising diagnostic tool to improve tumor marker efficiency.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12109515     DOI: 10.1007/s101470200021

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  7 in total

1.  Toward a functional annotation of the human genome using artificial transcription factors.

Authors:  Dong-ki Lee; Jin Woo Park; Youn-Jae Kim; Jiwon Kim; Yangsoon Lee; Jeonglim Kim; Jin-Soo Kim
Journal:  Genome Res       Date:  2003-12       Impact factor: 9.043

2.  Risk of colon cancer in hereditary non-polyposis colorectal cancer patients as predicted by fuzzy modeling: Influence of smoking.

Authors:  Rhonda M Brand; David D Jones; Henry T Lynch; Randall E Brand; Patrice Watson; Ramesh Ashwathnayaran; Hemant K Roy
Journal:  World J Gastroenterol       Date:  2006-07-28       Impact factor: 5.742

Review 3.  Blood based biomarkers beyond genomics for lung cancer screening.

Authors:  Samir M Hanash; Edwin Justin Ostrin; Johannes F Fahrmann
Journal:  Transl Lung Cancer Res       Date:  2018-06

4.  Serum amino acid profiles and their alterations in colorectal cancer.

Authors:  Alexander Benedikt Leichtle; Jean-Marc Nuoffer; Uta Ceglarek; Julia Kase; Tim Conrad; Helmut Witzigmann; Joachim Thiery; Georg Martin Fiedler
Journal:  Metabolomics       Date:  2011-09-16       Impact factor: 4.290

5.  Fuzzy logic: A "simple" solution for complexities in neurosciences?

Authors:  Saniya Siraj Godil; Muhammad Shahzad Shamim; Syed Ather Enam; Uvais Qidwai
Journal:  Surg Neurol Int       Date:  2011-02-26

6.  Combination of circulating tumor cells with serum carcinoembryonic antigen enhances clinical prediction of non-small cell lung cancer.

Authors:  Xi Chen; Xu Wang; Hua He; Ziling Liu; Ji-Fan Hu; Wei Li
Journal:  PLoS One       Date:  2015-05-21       Impact factor: 3.240

7.  Calsyntenin-1, clusterin and neutrophil gelatinase-associated lipocalin are candidate serological biomarkers for lung adenocarcinoma.

Authors:  Yen Chu; Yu-Heng Lai; Ming-Cheng Lee; Yu-Jung Yeh; Yao-Kuang Wu; Wayne Tsao; Chun-Yao Huang; Semon Wu
Journal:  Oncotarget       Date:  2017-11-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.